The Dark Side of Testosterone Deficiency: I. Metabolic Syndrome and Erectile Dysfunction
Open Access
- 2 January 2009
- journal article
- review article
- Published by Wiley in Journal of Andrology
- Vol. 30 (1), 10-22
- https://doi.org/10.2164/jandrol.108.005215
Abstract
The metabolic syndrome (MetS) is considered the most important public health threat of the 21st century. This syndrome is characterized by a cluster of cardiovascular risk factors including increased central abdominal obesity, elevated triglycerides, reduced high‐density lipoprotein, high blood pressure, increased fasting glucose, and hyperinsulinemia. These factors increase the risk of cardiovascular disease (CVD) and/or type 2 diabetes. Although the etiology of this syndrome is thought to stem from obesity and physical inactivity, the extent of interactions of the individual MetS components with one another remains poorly defined. Obesity, diabetes, hypogonadism, and specific hormone and metabolic profiles have been implicated in the pathophysiology of CVD. The evolving role of androgens in MetS and CVD is of paramount importance. Reduced androgen levels associated with hypogonadism or androgen deprivation therapy increase cardiovascular risk factors and produce marked adverse effects on cardiovascular function. MetS has been associated with hypogonadism and erectile dysfunction (ED), and MetS may be considered a risk factor for ED. It is suggested that MetS, diabetes, and CVD will increase in the upcoming decades. Thus, it is critically important to develop a better understanding of how obesity, diabetes and hypogonadism contribute to androgen deficiency and the various pathophysiologic states of vascular disease. In this review we discuss the current literature pertaining to androgen deficiency, MetS, and ED, because the relationship of these factors is of scientific and clinical importance. Specifically, we will focus on exploring the relationships between hypogonadism, obesity, MetS, and ED.Keywords
This publication has 100 references indexed in Scilit:
- The triad of erectile dysfunction, hypogonadism and the metabolic syndromeInternational Journal of Clinical Practice, 2008
- A Dose‐Response Study of Testosterone on Sexual Dysfunction and Features of the Metabolic Syndrome Using Testosterone Gel and Parenteral Testosterone UndecanoateJournal of Andrology, 2008
- Association of Overweight With Increased Risk of Coronary Heart Disease Partly Independent of Blood Pressure and Cholesterol LevelsA Meta-analysis of 21 Cohort Studies Including More Than 300 000 PersonsArchives of Internal Medicine, 2007
- Penile Oxygen Saturation in the Flaccid and Erect Penis in Men With and Without Erectile DysfunctionJournal of Andrology, 2007
- Metabolic syndrome and coronary heart disease risk in a population-based study of middle-aged men from France and Northern Ireland: A nested case-control study from the PRIME cohortDiabetes & Metabolism, 2006
- Psychobiologic Correlates of the Metabolic Syndrome and Associated Sexual DysfunctionEuropean Urology, 2006
- Metabolic syndrome and risk for heart failure in middle-aged menHeart, 2006
- Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinicInternational Journal of Impotence Research, 2005
- HYPOGONADISM AND METABOLIC SYNDROME: IMPLICATIONS FOR TESTOSTERONE THERAPYJournal of Urology, 2005
- Prevalence of the Metabolic Syndrome and Its Relation to All-Cause and Cardiovascular Mortality in Nondiabetic European Men and WomenArchives of Internal Medicine, 2004